 [1m([0morchestrator-angioedema-CLONAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes CLONAZEPAM increase or decrease the risk of angioedema?[0m
 [1m([0morchestrator-angioedema-CLONAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-CLONAZEPAM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-angioedema-CLONAZEPAM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does CLONAZEPAM increase or decrease the risk of angioedema?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-angioedema-CLONAZEPAM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes CLONAZEPAM increase or decrease the risk of angioedema?[0m
 [1m([0morchestrator-angioedema-CLONAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-CLONAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-angioedema-CLONAZEPAM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes CLONAZEPAM increase or decrease the risk of angioedema?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does CLONAZEPAM increase the risk of angioedema?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"CLONAZEPAM"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: CLONAZEPAM: adverse_reactions: While these findings are noteworthy, Hamilton Depression Rating Scale [0m[1;31m([0m[31mHAM-D[0m[1;31m)[0m[31m data collected in these trials revealed a larger decline in HAM-D scores in the [0m
[31mclonazepam group than the placebo group suggesting that clonazepam-treated patients were not experiencing a worsening or emergence of clinical depression. Other Adverse Events Observed During the [0m
[31mPremarketing Evaluation of Clonazepam Tablets in Panic Disorder: Following is a list of modified CIGY terms that reflect treatment-emergent adverse events reported by patients treated with clonazepam [0m
[31mtablets at multiple doses during clinical trials. All reported events are included except those already listed in Table [0m[1;31m3[0m[31m or elsewhere in labeling, those events for which a drug cause was remote, [0m
[31mthose event terms which were so general as to be uninformative, and events reported only once and which did not have a substantial probability of being acutely life-threatening. CLONAZEPAM: [0m
[31madverse_reactions: It is important to emphasize that, although the events occurred during treatment with clonazepam tablets, they were not necessarily caused by it. Events are further categorized by [0m
[31mbody system and listed in order of decreasing frequency. These adverse events were reported infrequently, which is defined as occurring in [0m[1;31m1[0m[31m/[0m[1;31m100[0m[31m to [0m[1;31m1[0m[31m/[0m[1;31m1000[0m[31m patients. CLONAZEPAM: adverse_reactions: Body[0m
[31mas a Whole: weight increase, accident, weight decrease, wound, edema, fever, shivering, abrasions, ankle edema, edema foot, edema periorbital, injury, malaise, pain, cellulitis, inflammation localized[0m
[31mCardiovascular Disorders: chest pain, hypotension postural Central and Peripheral Nervous System Disorders: migraine, paresthesia, drunkenness, feeling of enuresis, paresis, tremor, burning skin, [0m
[31mfalling, head fullness, hoarseness, hyperactivity, hypoesthesia, tongue thick, twitching Gastrointestinal System Disorders: abdominal discomfort, gastrointestinal inflammation, stomach upset, [0m
[31mtoothache, flatulence, pyrosis, saliva increased, tooth disorder, bowel movements frequent, pain pelvic, dyspepsia, hemorrhoids Hearing and Vestibular Disorders: vertigo, otitis, earache, motion [0m
[31msickness Heart Rate and Rhythm Disorders: palpitation Metabolic and Nutritional Disorders: thirst CLONAZEPAM: adverse_reactions: , gout Musculoskeletal System Disorders: back pain, fracture traumatic,[0m
[31msprains and strains, pain leg, pain nape, cramps muscle, cramps leg, pain ankle, pain shoulder, tendinitis, arthralgia, hypertonia, lumbago, pain feet, pain jaw, pain knee, swelling knee Platelet, [0m
[31mBleeding and Clotting Disorders: bleeding dermal Psychiatric Disorders: insomnia, organic disinhibition, anxiety, depersonalization, dreaming excessive, libido loss, appetite increased, libido [0m
[31mincreased, reactions decreased, aggression, apathy, disturbance in attention, excitement, anger, hunger abnormal, illusion, nightmares, sleep disorder, suicide ideation, yawning Reproductive [0m
[31mDisorders, Female: breast pain, menstrual irregularity Reproductive Disorders, Male: ejaculation decreased Resistance Mechanism Disorders: infection mycotic, infection viral, infection streptococcal, [0m
[31mherpes simplex infection, infectious mononucleosis, moniliasis Respir CLONAZEPAM: adverse_reactions: atory System Disorders: sneezing excessive, asthmatic attack, dyspnea, nosebleed, pneumonia, [0m
[31mpleurisy Skin and Appendages Disorders: acne flare, alopecia, xeroderma, dermatitis contact, flushing, pruritus, pustular reaction, skin burns, skin disorder Special Senses Other, Disorders: taste [0m
[31mloss Urinary System Disorders: dysuria, cystitis, polyuria, urinary incontinence, bladder dysfunction, urinary retention, urinary tract bleeding, urine discoloration Vascular [0m[1;31m([0m[31mExtracardiac[0m[1;31m)[0m[31m Disorders:[0m
[31mthrombophlebitis leg Vision Disorders: eye irritation, visual disturbance, diplopia, eye twitching, styes, visual field defect, xerophthalmia         [0m
[31mSOUR[0m[1;31mCE:C[0m[31mLONAZEPAM label[0m


[31mCONTENT: ENALAPRIL MALEATE: drug_interactions: Other Cardiovascular Agents Enalapril maleate has been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking [0m
[31magents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions. Agents Increasing Serum Potassium Enalapril attenuates potassium loss caused by thiazide-type[0m
[31mdiuretics. Potassium-sparing diuretics [0m[1;31m([0m[31me.g., spironolactone, triamterene, or amiloride[0m[1;31m)[0m[31m, potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum [0m
[31mpotassium. Therefore, if concomitant use of these agents is indicated because of demonstrated hypokalemia, they should be used with caution and with frequent monitoring of serum potassium. [0m
[31mPotassium-sparing agents should generally not be used in patients with heart failure receiving enalapril maleate. ENALAPRIL MALEATE: drug_interactions: Lithium Lithium toxicity has been reported in [0m
[31mpatients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors. A few cases of lithium toxicity have been reported in patients receiving concomitant [0m
[31menalapril maleate and lithium and were reversible upon discontinuation of both drugs. It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly [0m
[31mwith lithium. Gold Nitritoid reactions [0m[1;31m([0m[31msymptoms include facial flushing, nausea, vomiting and hypotension[0m[1;31m)[0m[31m have been reported rarely in patients on therapy with injectable gold [0m[1;31m([0m[31msodium [0m
[31maurothiomalate[0m[1;31m)[0m[31m and concomitant ACE inhibitor therapy including enalapril maleate. mTOR [0m[1;31m([0m[31mMammalian Target of Rapamycin[0m[1;31m)[0m[31m Inhibitors Patients receiving coadministration of ACE inhibitor and mTOR [0m
[31minhibitor [0m[1;31m([0m[31me.g. ENALAPRIL MALEATE: drug_interactions: temsirolimus, sirolimus, everolimus[0m[1;31m)[0m[31m therapy may be at increased risk for angioedema [0m[1;31m([0m[31msee WARNINGS, Head and Neck Angioedema [0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: LISINOPRIL: warnings: WARNINGS General Lisinopril Anaphylactoid and Possibly Related Reactions: Presumably because angiotensin-converting enzyme inhibitors affect the metabolism of [0m
[31meicosanoids and polypeptides, including endogenous bradykinin, patients receiving ACE inhibitors [0m[1;31m([0m[31mincluding lisinopril and hydrochlorothiazide tablets[0m[1;31m)[0m[31m may be subject to a variety of adverse [0m
[31mreactions, some of them serious. Head and Neck Angioedema: Angioedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported rarely in patients treated with angiotensin [0m
[31mconverting enzyme inhibitors, including lisinopril. This may occur at any time during treatment. ACE inhibitors have been associated with a higher rate of angioedema in Black than in non-Black [0m
[31mpatients. LISINOPRIL: warnings: In such cases lisinopril and hydrochlorothiazide tablets should be promptly discontinued and appropriate therapy and monitoring should be provided until complete and [0m
[31msustained resolution of signs and symptoms has occurred. Even in those instances where swelling of only the tongue is involved, without respiratory distress, patients may require prolonged observation[0m
[31msince treatment with antihistamines and corticosteroids may not be sufficient. Very rarely, fatalities have been reported due to angioedema associated with laryngeal edema or tongue edema. Patients [0m
[31mwith involvement of the tongue, glottis or larynx are likely to experience airway obstruction, especially those with a history of airway surgery. Where there is involvement of the tongue, glottis or [0m
[31mlarynx, likely to cause airway obstruction, subcutaneous epinephrine solution [0m[1;31m1:1000[0m[31m [0m[1;31m([0m[1;31m0.3[0m[31m mL to [0m[1;31m0[0m[31m. LISINOPRIL: warnings: [0m[1;31m5[0m[31m mL[0m[1;31m)[0m[31m and/or measures necessary to ensure a patent airway should be promptly [0m
[31mprovided [0m[1;31m([0m[31mSee ADVERSE REACTIONS . [0m[1;31m)[0m[31m Patients with a history of angioedema unrelated to ACE-inhibitor therapy may be at increased risk of angioedema while receiving an ACE inhibitor [0m[1;31m([0m[31msee also [0m
[31mINDICATIONS AND USAGE and CONTRAINDICATIONS [0m[1;31m)[0m[31m. Patients receiving coadministration of ACE inhibitor and mTOR [0m[1;31m([0m[31mmammalian target of rapamycin[0m[1;31m)[0m[31m inhibitor [0m[1;31m([0m[31me.g., temsirolimus, sirolimus, everolimus[0m[1;31m)[0m[31m [0m
[31mtherapy or a neprilysin inhibitor may be at increased risk for angioedema [0m[1;31m([0m[31msee PRECAUTIONS [0m[1;31m)[0m[31m. Intestinal Angioedema : Intestinal angioedema has been reported in patients treated with ACE inhibitors. [0m
[31mThese patients presented with abdominal pain [0m[1;31m([0m[31mwith or without nausea or vomiting[0m[1;31m)[0m[31m; in some cases there was no prior history of facial angioedema and C-[0m[1;31m1[0m[31m esterase levels were normal. LISINOPRIL: [0m
[31mwarnings: The angioedema was diagnosed by procedures including abdominal CT scan or ultrasound, or at surgery, and symptoms resolved after stopping the ACE inhibitor. Intestinal angioedema should be [0m
[31mincluded in the differential diagnosis of patients on ACE inhibitors presenting with abdominal pain. Anaphylactoid reactions during desensitization: Two patients undergoing desensitizing treatment [0m
[31mwith hymenoptera venom while receiving ACE inhibitors sustained life-threatening anaphylactoid reactions. In the same patients, these reactions were avoided when ACE inhibitors were temporarily [0m
[31mwithheld, but they reappeared upon inadvertent rechallenge. Anaphylactoid reactions during membrane exposure: Sudden and potentially life-threatening anaphylactoid reactions have been reported in some[0m
[31mpatients dialyzed with high-flux membranes and treated concomitantly with an ACE inhibitor. In such patients, dialysis must be stopped immediately, and aggressive therapy for anaphylactoid reactions [0m
[31mmust be initiated. LISINOPRIL: warnings: Symptoms have not been relieved by antihistamines in these situations. In these patients, consideration should be given to using a different type of dialysis [0m
[31mmembrane or a different class of antihypertensive agent. Anaphylactoid reactions have also been reported in patients undergoing low-density lipoprotein apheresis with dextran sulfate absorption. [0m
[31mHypotension and Related Effects Excessive hypotension was rarely seen in uncomplicated hypertensive patients but is a possible consequence of lisinopril use in salt/volume-depleted persons such as [0m
[31mthose treated vigorously with diuretics or patients on dialysis. [0m[1;31m([0m[31mSee PRECAUTIONS, Drug Interactions and ADVERSE REACTIONS .[0m[1;31m)[0m[31m Syncope has been reported in [0m[1;31m0.8[0m[31m percent of patients receiving lisinopril [0m
[31mand hydrochlorothiazide tablets. In patients with hypertension receiving lisinopril alone, the incidence of syncope was [0m[1;31m0.1[0m[31m percent.         [0m
[31mSOURCE:LISINOPRIL label[0m


[31mCONTENT: CLONAZEPAM: warnings: WARNINGS Risks from Concomitant Use with Opioids: Concomitant use of benzodiazepines, including clonazepam tablets, and opioids may result in profound sedation, [0m
[31mrespiratory depression, coma, and death. Because of these risks, reserve concomitant prescribing of benzodiazepines and opioids for patients for whom alternative treatment options are inadequate. [0m
[31mObservational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioids alone. If a decision is [0m
[31mmade to prescribe clonazepam tablets concomitantly with opioids, prescribe the lowest effective dosages and minimum durations of concomitant use, and follow patients closely for signs and symptoms of [0m
[31mrespiratory depression and sedation. CLONAZEPAM: warnings: Advise both patients and caregivers about the risks of respiratory depression and sedation when clonazepam tablets are used with opioids [0m[1;31m([0m[31msee[0m
[31mPRECAUTIONS: Information for Patients and PRECAUTIONS: Drug Interactions [0m[1;31m)[0m[31m. Abuse, Misuse, and Addiction: The use of benzodiazepines, including clonazepam tablets, exposes users to the risks of abuse,[0m
[31mmisuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines often [0m[1;31m([0m[31mbut not always[0m[1;31m)[0m[31m involve the use of doses greater than the maximum recommended dosage and commonly[0m
[31minvolve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes, including respiratory depression, [0m
[31moverdose, or death [0m[1;31m([0m[31msee DRUG ABUSE AND DEPENDENCE: Abuse [0m[1;31m)[0m[31m . Before prescribing clonazepam tablets and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction [0m[1;31m([0m[31me.g. [0m
[31mCLONAZEPAM: warnings: using a standardized screening tool[0m[1;31m)[0m[31m. Use of clonazepam tablets, particularly in patients at elevated risk, necessitates counseling about the risks and proper use of clonazepam [0m
[31mtablets along with monitoring for signs and symptoms of abuse, misuse, and addiction. Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances [0m
[31massociated with abuse, misuse, and addiction [0m[1;31m([0m[31me.g., opioid analgesics, stimulants[0m[1;31m)[0m[31m; and advise patients on the proper disposal of unused drug. If a substance use disorder is suspected, evaluate the [0m
[31mpatient and institute [0m[1;31m([0m[31mor refer them for[0m[1;31m)[0m[31m early treatment, as appropriate. Dependence and Withdrawal Reactions: To reduce the risk of withdrawal reactions, use a gradual taper to discontinue [0m
[31mclonazepam tablets or reduce the dosage [0m[1;31m([0m[31ma patient-specific plan should be used to taper the dose[0m[1;31m)[0m[31m [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION: Discontinuation or Dosage Reduction of Clonazepam Tablets [0m[1;31m)[0m[31m .        [0m
[31mSOUR[0m[1;31mCE:C[0m[31mLONAZEPAM label[0m


[31mCONTENT: ENALAPRIL MALEATE: precautions: Monitor renal function periodically in patients receiving enalapril and NSAID therapy. In a clinical pharmacology study, indomethacin or sulindac was [0m
[31madministered to hypertensive patients receiving enalapril maleate. In this study there was no evidence of a blunting of the antihypertensive action of enalapril maleate. However, reports suggest that [0m
[31mNSAIDs may diminish the antihypertensive effect of ACE inhibitors. Other Cardiovascular Agents Enalapril maleate has been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates,[0m
[31mcalcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions. Agents Increasing Serum Potassium Enalapril attenuates potassium loss caused[0m
[31mby thiazide-type diuretics. Potassium-sparing diuretics [0m[1;31m([0m[31me.g. ENALAPRIL MALEATE: precautions: spironolactone, triamterene, or amiloride[0m[1;31m)[0m[31m, potassium supplements, or potassium-containing salt [0m
[31msubstitutes may lead to significant increases in serum potassium. Therefore, if concomitant use of these agents is indicated because of demonstrated hypokalemia, they should be used with caution and [0m
[31mwith frequent monitoring of serum potassium. Potassium-sparing agents should generally not be used in patients with heart failure receiving enalapril maleate. Lithium Lithium toxicity has been [0m
[31mreported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors. A few cases of lithium toxicity have been reported in patients receiving [0m
[31mconcomitant enalapril maleate and lithium and were reversible upon discontinuation of both drugs. It is recommended that serum lithium levels be monitored frequently if enalapril is administered [0m
[31mconcomitantly with lithium. ENALAPRIL MALEATE: precautions: Gold Nitritoid reactions [0m[1;31m([0m[31msymptoms include facial flushing, nausea, vomiting and hypotension[0m[1;31m)[0m[31m have been reported rarely in patients on [0m
[31mtherapy with injectable gold [0m[1;31m([0m[31msodium aurothiomalate[0m[1;31m)[0m[31m and concomitant ACE inhibitor therapy including enalapril maleate. mTOR [0m[1;31m([0m[31mMammalian Target of Rapamycin[0m[1;31m)[0m[31m Inhibitors Patients receiving [0m
[31mcoadministration of ACE inhibitor and mTOR inhibitor [0m[1;31m([0m[31me.g., temsirolimus, sirolimus, everolimus[0m[1;31m)[0m[31m therapy may be at increased risk for angioedema [0m[1;31m([0m[31msee WARNINGS, Head and Neck Angioedema [0m[1;31m)[0m[31m. [0m
[31mCarcinogenesis, Mutagenesis, Impairment of Fertility There was no evidence of a tumorigenic effect when enalapril was administered for [0m[1;31m106[0m[31m weeks to male and female rats at doses up to [0m[1;31m90[0m[31m mg/kg/day or [0m
[31mfor [0m[1;31m94[0m[31m weeks to male and female mice at doses up to [0m[1;31m90[0m[31m and [0m[1;31m180[0m[31m mg/kg/day, respectively. ENALAPRIL MALEATE: precautions: These doses are [0m[1;31m26[0m[31m times [0m[1;31m([0m[31min rats and female mice[0m[1;31m)[0m[31m and [0m[1;31m13[0m[31m times [0m[1;31m([0m[31min male mice[0m[1;31m)[0m[31m [0m
[31mthe maximum recommended human daily dose [0m[1;31m([0m[31mMRHDD[0m[1;31m)[0m[31m when compared on a body surface area basis. Neither enalapril maleate nor the active diacid was mutagenic in the Ames microbial mutagen test with or [0m
[31mwithout metabolic activation. Enalapril was also negative in the following genotoxicity studies: rec-assay, reverse mutation assay with E. coli , sister chromatid exchange with cultured mammalian [0m
[31mcells, and the micronucleus test with mice, as well as in an in vivo cytogenic study using mouse bone marrow. There were no adverse effects on reproductive performance of male and female rats treated [0m
[31mwith up to [0m[1;31m90[0m[31m mg/kg/day of enalapril [0m[1;31m([0m[1;31m26[0m[31m times the MRHDD when compared on a body surface area basis[0m[1;31m)[0m[31m. Pregnancy Nursing Mothers Enalapril and enalaprilat have been detected in human breast milk. [0m
[31mENALAPRIL MALEATE: precautions: Because of the potential for serious adverse reactions in nursing infants from enalapril, a decision should be made whether to discontinue nursing or to discontinue [0m
[31menalapril maleate, taking into account the importance of the drug to the mother. Pediatric Use Neonates with a History of In Utero Exposure to Enalapril Maleate If oliguria or hypotension occurs, [0m
[31mdirect attention toward support of blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing hypotension and/or substituting for disordered renal [0m
[31mfunction. Enalapril, which crosses the placenta, has been removed from neonatal circulation by peritoneal dialysis with some clinical benefit, and theoretically may be removed by exchange transfusion,[0m
[31malthough there is no experience with the latter procedure. Antihypertensive effects of enalapril maleate have been established in hypertensive pediatric patients age [0m[1;31m1[0m[31m month to [0m[1;31m16[0m[31m years.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: CLONAZEPAM: nursing_mothers: Nursing Mothers: Risk Summary Clonazepam is excreted in human milk. There are reports of sedation, poor feeding and poor weight gain in infants exposed to [0m
[31mbenzodiazepines through breast milk. There are no data on the effects of clonazepam on milk production. The developmental and health benefits of breastfeeding should be considered along with the [0m
[31mmother's clinical need for clonazepam tablets and any potential adverse effects on the breastfed infant from clonazepam tablets or from the underlying maternal condition. Clinical Considerations [0m
[31mInfants exposed to clonazepam through breast milk should be monitored for sedation, poor feeding and poor weight gain.         [0m
[31mSOUR[0m[1;31mCE:C[0m[31mLONAZEPAM label[0m


[31mCONTENT: CLONAZEPAM: precautions: Although early studies reported an increased risk of congenital malformations with diazepam and chlordiazepoxide, there was no consistent pattern noted. In addition, [0m
[31mthe majority of more recent case-control and cohort studies of benzodiazepine use during pregnancy, which were adjusted for confounding exposures to alcohol, tobacco and other medications, have not [0m
[31mconfirmed these findings. Animal Data In three studies in which clonazepam was administered orally to pregnant rabbits at doses of [0m[1;31m0.2[0m[31m, [0m[1;31m1[0m[31m, [0m[1;31m5[0m[31m, or [0m[1;31m10[0m[31m mg/kg/day during the period of organogenesis, a [0m
[31msimilar pattern of malformations [0m[1;31m([0m[31mcleft palate, open eyelid, fused sternebrae and limb defects[0m[1;31m)[0m[31m was observed at all doses, in a low, non-dose-related incidence. CLONAZEPAM: precautions: The lowest [0m
[31mdose tested is less than the maximum recommended human dose [0m[1;31m([0m[31mMRHD[0m[1;31m)[0m[31m of [0m[1;31m20[0m[31m mg/day for seizure disorders and similar to the MRHD of [0m[1;31m4[0m[31m mg/day for panic disorder, on a mg/m [0m[1;31m2[0m[31m basis. Reductions in maternal [0m
[31mweight gain occurred at doses of [0m[1;31m5[0m[31m mg/kg/day or greater and reduction in embryofetal growth occurred in one study at a dose of [0m[1;31m10[0m[31m mg/kg/day. No adverse maternal or embryofetal effects were observed in[0m
[31mmice or rats following oral administration of clonazepam during organogenesis of doses up to [0m[1;31m15[0m[31m or [0m[1;31m40[0m[31m mg/kg/day, respectively [0m[1;31m([0m[1;31m4[0m[31m and [0m[1;31m20[0m[31m times the MRHD of [0m[1;31m20[0m[31m mg/day for seizure disorders and [0m[1;31m20[0m[31m and [0m[1;31m100[0m
[31mtimes the MRHD of [0m[1;31m4[0m[31m mg/day for panic disorder, respectively, on a mg/m [0m[1;31m2[0m[31m basis[0m[1;31m)[0m[31m. CLONAZEPAM: precautions: Data for other benzodiazepines suggest the possibility of adverse developmental effects [0m
[1;31m([0m[31mlong-term effects on neurobehavioral and immunological function[0m[1;31m)[0m[31m in animals following prenatal exposure to benzodiazepines. Nursing Mothers: Risk Summary Clonazepam is excreted in human milk. There [0m
[31mare reports of sedation, poor feeding and poor weight gain in infants exposed to benzodiazepines through breast milk. There are no data on the effects of clonazepam on milk production. The [0m
[31mdevelopmental and health benefits of breastfeeding should be considered along with the mother's clinical need for clonazepam tablets and any potential adverse effects on the breastfed infant from [0m
[31mclonazepam tablets or from the underlying maternal condition. Clinical Considerations Infants exposed to clonazepam through breast milk should be monitored for sedation, poor feeding and poor weight [0m
[31mgain. CLONAZEPAM: precautions: Pediatric Use: Because of the possibility that adverse effects on physical or mental development could become apparent only after many years, a benefit-risk [0m
[31mconsideration of the long-term use of clonazepam tablets is important in pediatric patients being treated for seizure disorder [0m[1;31m([0m[31msee INDICATIONS AND USAGE and DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. Safety and [0m
[31meffectiveness in pediatric patients with panic disorder below the age of [0m[1;31m18[0m[31m have not been established. Geriatric Use: Clinical studies of clonazepam tablets did not include sufficient numbers of [0m
[31msubjects aged [0m[1;31m65[0m[31m and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and [0m
[31myounger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, [0m
[31mrenal, or cardiac function, and of concomitant disease or other drug therapy. CLONAZEPAM: precautions: Because clonazepam undergoes hepatic metabolism, it is possible that liver disease will impair [0m
[31mclonazepam elimination. Metabolites of clonazepam tablets are excreted by the kidneys; to avoid their excess accumulation, caution should be exercised in the administration of the drug to patients [0m
[31mwith impaired renal function. Because elderly patients are more likely to have decreased hepatic and/or renal function, care should be taken in dose selection, and it may be useful to assess hepatic [0m
[31mand/or renal function at the time of dose selection. Sedating drugs may cause confusion and over-sedation in the elderly; elderly patients generally should be started on low doses of clonazepam [0m
[31mtablets and observed closely.         [0m
[31mSOUR[0m[1;31mCE:C[0m[31mLONAZEPAM label[0m


[31mCONTENT: LISINOPRIL: drug_interactions: Patients receiving the combination of losartan and lisinopril did not obtain any additional benefit compared to monotherapy for the combined endpoint of decline[0m
[31min GFR, end state renal disease, or death, but experienced an increased incidence of hyperkalemia and acute kidney injury compared with the monotherapy group. In general, avoid combined use of RAS [0m
[31minhibitors. Monitor blood pressure, renal function, and electrolytes in patients on lisinopril and hydrochlorothiazide tablets and other agents that affect the RAS. Do not coadminister aliskiren with [0m
[31mlisinopril and hydrochlorothiazide tablets in patients with diabetes. Avoid use of aliskiren with PRINZIDE in patients with renal impairment [0m[1;31m([0m[31mGFR <[0m[1;31m60[0m[31m ml/min[0m[1;31m)[0m[31m. Other Agents: Lisinopril has been used [0m
[31mconcomitantly with nitrates and/or digoxin without evidence of clinically significant adverse interactions. LISINOPRIL: drug_interactions: No meaningful clinically important pharmacokinetic [0m
[31minteractions occurred when lisinopril was used concomitantly with propranolol, digoxin, or hydrochlorothiazide. The presence of food in the stomach does not alter the bioavailability of lisinopril. [0m
[31mAgents Increasing Serum Potassium: Lisinopril attenuates potassium loss caused by thiazide-type diuretics. Use of lisinopril with potassium-sparing diuretics [0m[1;31m([0m[31me.g., spironolactone, eplerenone, [0m
[31mtriamterene, or amiloride[0m[1;31m)[0m[31m, potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. Therefore, if concomitant use of these agents is [0m
[31mindicated, because of demonstrated hypokalemia, they should be used with caution and with frequent monitoring of serum potassium. Lithium: Lithium toxicity has been reported in patients receiving [0m
[31mlithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors. LISINOPRIL: drug_interactions: Lithium toxicity was usually reversible upon discontinuation of lithium and[0m
[31mthe ACE inhibitor. It is recommended that serum lithium levels be monitored frequently if lisinopril is administered concomitantly with lithium. Gold: Nitritoid reactions [0m[1;31m([0m[31msymptoms include facial [0m
[31mflushing, nausea, vomiting and hypotension[0m[1;31m)[0m[31m have been reported rarely in patients on therapy with injectable gold [0m[1;31m([0m[31msodium aurothiomalate[0m[1;31m)[0m[31m and concomitant ACE inhibitor therapy including lisinopril and[0m
[31mhydrochlorothiazide tablets. mTOR [0m[1;31m([0m[31mmammalian target of rapamycin[0m[1;31m)[0m[31m inhibitors: Patients receiving coadministration of ACE inhibitor and mTOR inhibitor [0m[1;31m([0m[31me.g., temsirolimus, sirolimus, everolimus[0m[1;31m)[0m[31m [0m
[31mtherapy may be at increased risk for angioedema. [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m Neprilysin Inhibitors: Patients taking concomitant neprilysin inhibitors may be at increased risk for angioedema. LISINOPRIL: [0m
[31mdrug_interactions: [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m Hydrochlorothiazide When administered concurrently the following drugs may interact with thiazide diuretics. Alcohol, barbiturates, or narcotics - potentiation of [0m
[31morthostatic hypotension may occur. Antidiabetic drugs [0m[1;31m([0m[31moral agents and insulin[0m[1;31m)[0m[31m - dosage adjustment of the antidiabetic drug may be required. Other antihypertensive drugs - additive effect or [0m
[31mpotentiation. Cholestyramine and colestipol resins - Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins. Single doses of either cholestyramine or colestipol [0m
[31mresins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to [0m[1;31m85[0m[31m% and [0m[1;31m43[0m[31m%, respectively. Corticosteroids, ACTH - intensified electrolyte depletion, [0m
[31mparticularly hypokalemia. Pressor amines [0m[1;31m([0m[31me.g. LISINOPRIL: drug_interactions: norepinephrine[0m[1;31m)[0m[31m - possible decreased response to pressor amines but not sufficient to preclude their use. Skeletal muscle [0m
[31mrelaxants, nondepolarizing [0m[1;31m([0m[31me.g., tubocurarine[0m[1;31m)[0m[31m - possible increased responsiveness to the muscle relaxant. Lithium - should not generally be given with diuretics. Diuretic agents reduce the renal [0m
[31mclearance of lithium and add a high risk of lithium toxicity. Refer to the package insert for lithium preparations before use of such preparations with lisinopril and hydrochlorothiazide tablets. [0m
[31mNon-steroidal Anti-inflammatoryDrugs - In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, [0m
[31mpotassium-sparing and thiazide diuretics.         [0m
[31mSOURCE:LISINOPRIL label[0m


[31mCONTENT: ENALAPRIL MALEATE: warnings: WARNINGS Anaphylactoid and Possibly Related Reactions Presumably because angiotensin-converting enzyme inhibitors affect the metabolism of eicosanoids and [0m
[31mpolypeptides, including endogenous bradykinin, patients receiving ACE inhibitors [0m[1;31m([0m[31mincluding enalapril maleate[0m[1;31m)[0m[31m may be subject to a variety of adverse reactions, some of them serious. Head and Neck [0m
[31mAngioedema Angioedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported in patients treated with angiotensin-converting enzyme inhibitors, including enalapril maleate. [0m
[31mThis may occur at any time during treatment. In such cases enalapril maleate should be promptly discontinued and appropriate therapy and monitoring should be provided until complete and sustained [0m
[31mresolution of signs and symptoms has occurred. ENALAPRIL MALEATE: warnings: In instances where swelling has been confined to the face and lips the condition has generally resolved without treatment, [0m
[31malthough antihistamines have been useful in relieving symptoms. Angioedema associated with laryngeal edema may be fatal. Where there is involvement of the tongue, glottis or larynx, likely to cause [0m
[31mairway obstruction, appropriate therapy, e.g., subcutaneous epinephrine solution [0m[1;31m1:1000[0m[31m [0m[1;31m([0m[1;31m0.3[0m[31m mL to [0m[1;31m0.5[0m[31m mL[0m[1;31m)[0m[31m and/or measures necessary to ensure a patent airway, should be promptly provided [0m[1;31m([0m[31msee ADVERSE[0m
[31mREACTIONS [0m[1;31m)[0m[31m. Patients receiving coadministration of ACE inhibitor and mTOR [0m[1;31m([0m[31mmammalian target of rapamycin[0m[1;31m)[0m[31m inhibitor [0m[1;31m([0m[31me.g., temsirolimus, sirolimus, everolimus[0m[1;31m)[0m[31m therapy or a neprilysin inhibitor may [0m
[31mbe at increased risk for angioedema [0m[1;31m([0m[31msee PRECAUTIONS [0m[1;31m)[0m[31m. ENALAPRIL MALEATE: warnings: Intestinal Angioedema Intestinal angioedema has been reported in patients treated with ACE inhibitors. These [0m
[31mpatients presented with abdominal pain [0m[1;31m([0m[31mwith or without nausea or vomiting[0m[1;31m)[0m[31m; in some cases there was no prior history of facial angioedema and C1 esterase levels were normal. The angioedema was [0m
[31mdiagnosed by procedures including abdominal CT scan or ultrasound, or at surgery, and symptoms resolved after stopping the ACE inhibitor. Intestinal angioedema should be included in the differential [0m
[31mdiagnosis of patients on ACE inhibitors presenting with abdominal pain. Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk of angioedema while receiving [0m
[31man ACE inhibitor [0m[1;31m([0m[31msee INDICATIONS AND USAGE and CONTRAINDICATIONS [0m[1;31m)[0m[31m. Anaphylactoid Reactions During Desensitization Two patients undergoing desensitizing treatment with hymenoptera venom while [0m
[31mreceiving ACE inhibitors sustained life-threatening anaphylactoid reactions. ENALAPRIL MALEATE: warnings: In the same patients, these reactions were avoided when ACE inhibitors were temporarily [0m
[31mwithheld, but they reappeared upon inadvertent rechallenge. Anaphylactoid Reactions During Membrane Exposure Anaphylactoid reactions have been reported in patients dialyzed with high-flux membranes [0m
[31mand treated concomitantly with an ACE inhibitor. Anaphylactoid reactions have also been reported in patients undergoing low-density lipoprotein apheresis with dextran sulfate absorption. Hypotension [0m
[31mExcessive hypotension is rare in uncomplicated hypertensive patients treated with enalapril maleate alone. Patients with heart failure given enalapril maleate commonly have some reduction in blood [0m
[31mpressure, especially with the first dose, but discontinuation of therapy for continuing symptomatic hypotension usually is not necessary when dosing instructions are followed; caution should be [0m
[31mobserved when initiating therapy [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. ENALAPRIL MALEATE: warnings: Patients at risk for excessive hypotension, sometimes associated with oliguria and/or progressive [0m
[31mazotemia, and rarely with acute renal failure and/or death, include those with the following conditions or characteristics: heart failure, hyponatremia, high-dose diuretic therapy, recent intensive [0m
[31mdiuresis or increase in diuretic dose, renal dialysis, or severe volume and/or salt depletion of any etiology. It may be advisable to eliminate the diuretic [0m[1;31m([0m[31mexcept in patients with heart failure[0m[1;31m)[0m[31m, [0m
[31mreduce the diuretic dose or increase salt intake cautiously before initiating therapy with enalapril maleate in patients at risk for excessive hypotension who are able to tolerate such adjustments [0m
[1;31m([0m[31msee PRECAUTIONS, Drug Interactions and ADVERSE REACTIONS [0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: CLONAZEPAM: boxed_warning: WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS Concomitant use of benzodiazepines and [0m
[31mopioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. [0m
[31mLimit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation [0m[1;31m([0m[31msee WARNINGS and PRECAUTIONS [0m[1;31m)[0m[31m. The use of benzodiazepines, [0m
[31mincluding clonazepam tablets, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other[0m
[31mmedications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. CLONAZEPAM: boxed_warning: Before prescribing clonazepam tablets and [0m
[31mthroughout treatment, assess each patient’s risk for abuse, misuse, and addiction [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m . The continued use of benzodiazepines, including clonazepam tablets, may lead to clinically [0m
[31msignificant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Abrupt discontinuation or rapid dosage reduction of clonazepam [0m
[31mtablets after continued use may precipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue clonazepam tablets[0m
[31mor reduce the dosage [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION and WARNINGS [0m[1;31m)[0m[31m .         [0m
[31mSOUR[0m[1;31mCE:C[0m[31mLONAZEPAM label[0m


[31mCONTENT: CLONAZEPAM: adverse_reactions: † Indicates that the p-value for the dose-trend test [0m[1;31m([0m[31mCochran-Mantel-Haenszel[0m[1;31m)[0m[31m for adverse event incidence was ≤ [0m[1;31m0.10[0m[31m. ‡ Denominators for events in [0m
[31mgender-specific systems are: n = [0m[1;31m240[0m[31m [0m[1;31m([0m[31mclonazepam[0m[1;31m)[0m[31m, [0m[1;31m102[0m[31m [0m[1;31m([0m[31mplacebo[0m[1;31m)[0m[31m for male, and [0m[1;31m334[0m[31m [0m[1;31m([0m[31mclonazepam[0m[1;31m)[0m[31m, [0m[1;31m192[0m[31m [0m[1;31m([0m[31mplacebo[0m[1;31m)[0m[31m for female. CLONAZEPAM: adverse_reactions: Clonazepam Maximum Daily Dose Adverse Event by[0m
[31mBody System < [0m[1;31m1[0m[31m mg n = [0m[1;31m96[0m[31m % [0m[1;31m1[0m[31m - < [0m[1;31m2[0m[31m mg n = [0m[1;31m129[0m[31m % [0m[1;31m2[0m[31m - < [0m[1;31m3[0m[31m mg n = [0m[1;31m113[0m[31m % ≥ [0m[1;31m3[0m[31m mg n = [0m[1;31m235[0m[31m % All Clonazepam Tablets Groups N = [0m[1;31m574[0m[31m % Placebo N = [0m[1;31m294[0m[31m % Central & Peripheral Nervous System Somnolence † [0m[1;31m26[0m[31m [0m[1;31m35[0m[31m [0m
[1;31m50[0m[31m [0m[1;31m36[0m[31m [0m[1;31m37[0m[31m [0m[1;31m10[0m[31m Dizziness [0m[1;31m5[0m[31m [0m[1;31m5[0m[31m [0m[1;31m12[0m[31m [0m[1;31m8[0m[31m [0m[1;31m8[0m[31m [0m[1;31m4[0m[31m Coordination Abnormal † [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m7[0m[31m [0m[1;31m9[0m[31m [0m[1;31m6[0m[31m [0m[1;31m0[0m[31m Ataxia † [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m8[0m[31m [0m[1;31m8[0m[31m [0m[1;31m5[0m[31m [0m[1;31m0[0m[31m Dysarthria † [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m4[0m[31m [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m Psychiatric Depression [0m[1;31m7[0m[31m [0m[1;31m6[0m[31m [0m[1;31m8[0m[31m [0m[1;31m8[0m[31m [0m[1;31m7[0m[31m [0m[1;31m1[0m[31m Memory Disturbance [0m[1;31m2[0m[31m [0m[1;31m5[0m[31m [0m[1;31m2[0m[31m [0m[1;31m5[0m[31m [0m[1;31m4[0m[31m [0m[1;31m2[0m[31m Nervous [0m
[31mCLONAZEPAM: adverse_reactions: ness [0m[1;31m1[0m[31m [0m[1;31m4[0m[31m [0m[1;31m3[0m[31m [0m[1;31m4[0m[31m [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m Intellectual Ability Reduced [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m4[0m[31m [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m Emotional Lability [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m Libido Decreased [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m Confusion [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m Respiratory System Upper [0m
[31mRespiratory Tract Infection † [0m[1;31m10[0m[31m [0m[1;31m10[0m[31m [0m[1;31m7[0m[31m [0m[1;31m6[0m[31m [0m[1;31m8[0m[31m [0m[1;31m4[0m[31m Sinusitis [0m[1;31m4[0m[31m [0m[1;31m2[0m[31m [0m[1;31m8[0m[31m [0m[1;31m4[0m[31m [0m[1;31m4[0m[31m [0m[1;31m3[0m[31m Rhinitis [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m [0m[1;31m4[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m Coughing [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m4[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m Pharyngitis [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m Bronchitis [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m Gastrointestinal System Constipation † [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m5[0m[31m [0m
[1;31m3[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m Appetite Decreased [0m[1;31m1[0m[31m CLONAZEPAM: adverse_reactions: [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m Abdominal Pain † [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m Body as a Whole Fatigue [0m[1;31m9[0m[31m [0m[1;31m6[0m[31m [0m[1;31m7[0m[31m [0m[1;31m7[0m[31m [0m[1;31m7[0m[31m [0m[1;31m4[0m[31m Allergic Reaction [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m [0m[1;31m4[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m Musculoskeletal Myalgia [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m4[0m[31m [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m
[31mResistance Mechanism Disorders Influenza [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m [0m[1;31m5[0m[31m [0m[1;31m5[0m[31m [0m[1;31m4[0m[31m [0m[1;31m3[0m[31m Urinary System Micturition Frequency [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m Urinary Tract Infection † [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m Vision Disorders Blurred Vision [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m Reproductive [0m
[31mDisorders ‡ Female Dysmenorrhea [0m[1;31m0[0m[31m [0m[1;31m6[0m[31m [0m[1;31m5[0m[31m [0m[1;31m2[0m[31m [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m Colpitis [0m[1;31m4[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m Male Ejaculation Delayed CLONAZEPAM: adverse_reactions: [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m Impotence [0m[1;31m3[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m Commonly Observed Adverse Events: Table [0m[1;31m4[0m[31m. [0m
[31mIncidence of Most Commonly Observed Adverse Events * in Acute Therapy in Pool of [0m[1;31m6[0m[31m- to [0m[1;31m9[0m[31m-Week Trials * Treatment-emergent events for which the incidence in the clonazepam patients was ≥ [0m[1;31m5[0m[31m% and at [0m
[31mleast twice that in the placebo patients. CLONAZEPAM: adverse_reactions: Adverse Event Clonazepam [0m[1;31m([0m[31mN = [0m[1;31m574[0m[1;31m)[0m[31m Placebo [0m[1;31m([0m[31mN = [0m[1;31m294[0m[1;31m)[0m[31m Somnolence [0m[1;31m37[0m[31m% [0m[1;31m10[0m[31m% Depression [0m[1;31m7[0m[31m% [0m[1;31m1[0m[31m% Coordination Abnormal [0m[1;31m6[0m[31m% [0m[1;31m0[0m[31m% Ataxia [0m[1;31m5[0m[31m% [0m
[1;31m0[0m[31m% Treatment-Emergent Depressive Symptoms: In the pool of two short-term placebo-controlled trials, adverse events classified under the preferred term “depression” were reported in [0m[1;31m7[0m[31m% of clonazepam [0m
[31mtablets-treated patients compared to [0m[1;31m1[0m[31m% of placebo-treated patients, without any clear pattern of dose relatedness. In these same trials, adverse events classified under the preferred term [0m
[31m“depression” were reported as leading to discontinuation in [0m[1;31m4[0m[31m% of clonazepam tablets-treated patients compared to [0m[1;31m1[0m[31m% of placebo-treated patients.         [0m
[31mSOUR[0m[1;31mCE:C[0m[31mLONAZEPAM label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Clonazepam does not list angioedema as a reported adverse reaction. The adverse reactions listed for clonazepam include various other effects but do not mention an increase or decrease in the [0m
[32mrisk of angioedema.[0m
[32mSOURCE: CLONAZEPAM label[0m
[32mEXTRACT_START_END: CLONAZEPAM: adverse_reactions: Body as a Whole: [0m[32m...[0m[32m Vision Disorders: eye irritation, visual disturbance, diplopia, eye twitching, styes, visual field defect, xerophthalmia[0m
*[1m([0morchestrator-angioedema-CLONAZEPAM[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Clonazepam does not list angioedema as a reported adverse reaction. [0m
[34mThe adverse reactions listed for clonazepam include various other effects but do not mention an increase or decrease in the risk of angioedema.[0m
[34mSOURCE: CLONAZEPAM label[0m
[34mEXTRACT_START_END: CLONAZEPAM: adverse_reactions: Body as a Whole: [0m[34m...[0m[34m Vision Disorders: eye irritation, visual disturbance, diplopia, eye twitching, styes, visual field defect, xerophthalmia[0m
 [1m([0morchestrator-angioedema-CLONAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-CLONAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-angioedema-CLONAZEPAM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does CLONAZEPAM increase or decrease the risk of angioedema?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether CLONAZEPAM increases or decreases the risk of angioedema."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that Clonazepam does not list angioedema as a reported adverse reaction. The adverse reactions listed for clonazepam include various other effects but do not mention an [0m
[32mincrease or decrease in the risk of angioedema."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"According to FDA data, Clonazepam does not list angioedema as a reported adverse reaction, which means there is no information available to suggest that Clonazepam increases or [0m
[32mdecreases the risk of angioedema."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-angioedema-CLONAZEPAM[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-angioedema-CLONAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-angioedema-CLONAZEPAM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-angioedema-CLONAZEPAM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does CLONAZEPAM increase or decrease the risk of angioedema?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether CLONAZEPAM increases or decreases the risk of angioedema."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that Clonazepam does not list angioedema as a reported adverse reaction. The adverse reactions listed for clonazepam include various other effects but do not mention an [0m
[34mincrease or decrease in the risk of angioedema."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"According to FDA data, Clonazepam does not list angioedema as a reported adverse reaction, which means there is no information available to suggest that Clonazepam increases or [0m
[34mdecreases the risk of angioedema."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does CLONAZEPAM increase or decrease the risk of angioedema?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether CLONAZEPAM increases or decreases the risk of angioedema.[0m
[1;31m2[0m[31m. FDAHandler responded that Clonazepam does not list angioedema as a reported adverse reaction. The adverse reactions listed for clonazepam include various other effects but do not mention an [0m
[31mincrease or decrease in the risk of angioedema.[0m
[31m        -----[0m
[31m        Final answer: According to FDA data, Clonazepam does not list angioedema as a reported adverse reaction, which means there is no information available to suggest that Clonazepam increases or [0m
[31mdecreases the risk of angioedema.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-angioedema-CLONAZEPAM[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-angioedema-CLONAZEPAM[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-angioedema-CLONAZEPAM[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-angioedema-CLONAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-angioedema-CLONAZEPAM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mThe final answer to the question [0m[32m"Does CLONAZEPAM increase or decrease the risk of angioedema?"[0m[32m is that according to FDA data, Clonazepam does not list angioedema as a reported adverse reaction. This [0m
[32mmeans there is no information available to suggest that Clonazepam increases or decreases the risk of angioedema.[0m
